KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Emergent BioSolutions (EBS) EPS (Weighted Average and Diluted) (2016 - 2025)

Emergent BioSolutions (EBS) has 16 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.96 in Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 113.33% year-over-year to -$0.96; the TTM value through Dec 2025 reached $0.93, up 125.83%, while the annual FY2025 figure was $0.93, 125.83% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.96 in Q4 2025 per EBS's latest filing, down from $0.9 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $3.29 in Q4 2021 and bottomed at -$5.38 in Q2 2024.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.9, with a median of -$0.6 recorded in 2021.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 633.33% in 2021, then plummeted 5200.0% in 2023.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $3.29 in 2021, then crashed by 145.9% to -$1.51 in 2022, then skyrocketed by 41.72% to -$0.88 in 2023, then surged by 48.86% to -$0.45 in 2024, then crashed by 113.33% to -$0.96 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.96 in Q4 2025, $0.9 in Q3 2025, and -$0.2 in Q2 2025.